Panoply™ Human PDE2A Over-expressing Stable Cell Line

Phosphodiesterase 2 (PDE2A) regulates the levels of cAMP and cGMP. Recent studies have revealed that it participates in the regulation of mitochondrial function and is closely associated with the progression of various types of tumors. In this study, researchers evaluated the prognostic significance and biological effects of PDE2A in hepatocellular carcinoma (HCC). The results demonstrated that PDE2A expression is downregulated across 25 different cancer types, including HCC. In the context of HCC, low expression of PDE2A was identified as a protective factor and was negatively correlated with serum AFP levels, tumor status, vascular invasion, histological grade, and pathological stage. Furthermore, tumors exhibiting low PDE2A expression were characterized by diminished immune function. Subsequently, the researchers utilized Receiver Operating Characteristic (ROC) curves to assess the diagnostic utility of PDE2A in HCC. Compared to patients with high PDE2A expression, those with low PDE2A expression exhibited a poorer prognosis. Additionally, Gene Ontology (GO) functional enrichment analysis indicated that PDE2A is involved in extracellular matrix (ECM) assembly, phylogenetic processes, and ERK-related signaling pathways, suggesting that PDE2A may regulate HCC growth and metastasis through these specific mechanisms. In vitro experiments further confirmed that, in two HCC cell lines (HLF and SNU-368), the overexpression of PDE2A inhibited cell proliferation, colony formation, migration, and invasion capabilities; conversely, the suppression of PDE2A expression yielded the opposite effects. These findings indicate that PDE2A plays a pivotal role in regulating the proliferation and metastasis of HCC, positioning it as a promising candidate biomarker for HCC prognostic prediction as well as a potential therapeutic target.

Here, researchers constructed PDE2A-overexpressing SNU-368 and HLF cells, and validated them via RT-qPCR and Western Blot (Figure 1A). To verify the impact of PDE2A on HCC cell lines, the researchers employed the MTS assay to compare the cell proliferation rates between the EV group and the PDE2A-overexpressing group. The results demonstrated that the proliferation of the PDE2A-overexpressing HCC cell lines was inhibited (Figure 1B). Colony formation assays further confirmed that the overexpression of PDE2A suppressed the colony-forming ability of the HCC SNU-368 and HLF cell lines (Figure 1C). Cell migration and invasion assays indicated that both the migration and invasion of the PDE2A-overexpressing HCC SNU-368 and HLF cell lines were inhibited (Figure 1D, E). To investigate the specific mechanisms by which PDE2A regulates HCC cell proliferation and migration, the researchers performed MitoTracker staining to observe mitochondrial morphology. The results revealed that in the PDE2A-overexpressing cells, mitochondria exhibited a more fragmented state (Figure 1F), accompanied by a decrease in ATP levels (Figure 1G).

Figure 1. Overexpression of PDE2A inhibits the proliferation, colony formation, migration, and invasion of HCC cell lines by regulating mitochondrial morphology and ATP content. (Chen L, et al., 2022)